Molecular AI, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.
Molecular AI, Discovery Sciences, R&D, AstraZeneca, Cambridge, UK.
Curr Opin Struct Biol. 2023 Jun;80:102575. doi: 10.1016/j.sbi.2023.102575. Epub 2023 Mar 24.
In this mini review, we capture the latest progress of applying artificial intelligence (AI) techniques based on deep learning architectures to molecular de novo design with a focus on integration with experimental validation. We will cover the progress and experimental validation of novel generative algorithms, the validation of QSAR models and how AI-based molecular de novo design is starting to become connected with chemistry automation. While progress has been made in the last few years, it is still early days. The experimental validations conducted thus far should be considered proof-of-principle, providing confidence that the field is moving in the right direction.
在这篇迷你综述中,我们捕捉到了最新的应用人工智能(AI)技术的进展,这些技术基于深度学习架构,重点是与实验验证相结合,用于分子从头设计。我们将涵盖新型生成算法的进展和实验验证、QSAR 模型的验证,以及基于 AI 的分子从头设计如何开始与化学自动化相结合。虽然在过去几年中已经取得了进展,但现在还为时过早。到目前为止进行的实验验证应被视为原理验证,这为该领域朝着正确的方向发展提供了信心。